PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
58.715 USD
-0.46 (-0.79%)
Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 192 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
Of the past 5 years PBH 4 years were profitable.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.21%, PBH belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
With an excellent Return On Equity value of 11.48%, PBH belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
With an excellent Return On Invested Capital value of 7.95%, PBH belongs to the best of the industry, outperforming 85.94% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is significantly below the industry average of 13.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH has a Profit Margin of 19.02%. This is amongst the best in the industry. PBH outperforms 91.15% of its industry peers.
PBH's Profit Margin has improved in the last couple of years.
PBH has a better Operating Margin (31.15%) than 94.27% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
PBH has a better Gross Margin (56.13%) than 65.63% of its industry peers.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PBH has less shares outstanding
PBH has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
PBH has an Altman-Z score of 2.55. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.55, PBH is doing good in the industry, outperforming 67.71% of the companies in the same industry.
PBH has a debt to FCF ratio of 3.79. This is a good value and a sign of high solvency as PBH would need 3.79 years to pay back of all of its debts.
The Debt to FCF ratio of PBH (3.79) is better than 85.94% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
The Debt to Equity ratio of PBH (0.55) is worse than 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.55 |
ROIC/WACC0.96
WACC8.3%
2.3 Liquidity
PBH has a Current Ratio of 4.38. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.38, PBH is in the better half of the industry, outperforming 64.06% of the companies in the same industry.
PBH has a Quick Ratio of 2.99. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
PBH's Quick ratio of 2.99 is in line compared to the rest of the industry. PBH outperforms 55.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.15% over the past year.
PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
The Revenue has been growing slightly by 1.10% in the past year.
PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
The Earnings Per Share is expected to grow by 3.45% on average over the next years.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.11% on average per year.
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 12.88 indicates a correct valuation of PBH.
Compared to the rest of the industry, the Price/Earnings ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 87.50% of the companies listed in the same industry.
PBH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.51.
PBH is valuated correctly with a Price/Forward Earnings ratio of 12.18.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 84.38% of the companies in the same industry.
PBH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.88 | ||
| Fwd PE | 12.18 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 88.02% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 89.58% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.79 | ||
| EV/EBITDA | 10 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)19.19
PEG (5Y)1.45
EPS Next 2Y3.17%
EPS Next 3Y2.82%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:PBH (11/19/2025, 12:06:02 PM)
58.715
-0.46 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change-0.69%
Ins Owners1.29%
Ins Owner Change1.87%
Market Cap2.89B
Revenue(TTM)1.14B
Net Income(TTM)213.00M
Analysts84
Price Target82.42 (40.37%)
Short Float %3.12%
Short Ratio3.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)-3.35%
PT rev (3m)-10.02%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-9.33%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-5.34%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-2.43%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-3.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.88 | ||
| Fwd PE | 12.18 | ||
| P/S | 2.58 | ||
| P/FCF | 10.79 | ||
| P/OCF | 10.48 | ||
| P/B | 1.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10 |
EPS(TTM)4.56
EY7.77%
EPS(NY)4.82
Fwd EY8.21%
FCF(TTM)5.44
FCFY9.27%
OCF(TTM)5.6
OCFY9.54%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)19.19
PEG (5Y)1.45
Graham Number62.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.55 |
F-Score8
WACC8.3%
ROIC/WACC0.96
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.48%
EBIT Next 5Y2.99%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 0.67% in the next year.